U.S. court reverses Massachusetts ban on Zogenix pain drug

Tue Apr 15, 2014 7:06pm EDT

Related Topics

(Reuters) - A U.S. District Court judge on Tuesday stopped Massachusetts from implementing a ban on the sale of Zogenix Inc's prescription painkiller Zohydro, saying federal law superseded the state's action.

The company's shares climbed about 9 percent to $2.54 in after-hours trading.

Massachusetts Governor Deval Patrick had announced a ban on the drug, formally declaring a public health emergency on March 27 stemming from abuse of opioids in the New England state.

The U.S. District Court for Massachusetts granted a preliminary injunction against the ban, saying that by imposing its own conclusion about the safety and efficacy of Zohydro, the state was obstructing the U.S. Food and Drug Administration's constitutionally mandated charge.

The federal court order goes into effect on April 22.

"Although the ban may prevent someone from misusing the drug, the ban prevents all in need of its special attributes from receiving the pain relief Zohydro ER offers," Judge Rya Zobel said.

The injunction comes in the midst of a furor over Zohydro as the United States grapples with a rise in opioid abuse. The class of drugs includes not only powerful prescription painkillers but also heroin. Massachusetts has seen a spike in the number of opioid- and heroin-related deaths.

Zohydro, an extended-release form of hydrocodone, has come under scrutiny from members of the U.S. Congress, state attorneys general, medical groups and drug treatment experts seeking to block its use.

Although intended for release over a 12-hour period, the medicine can be crushed and inhaled or injected, making a full dose available immediately.

FDA last year approved Zohydro, Zogenix's sole product on the market, despite concerns from an advisory panel over the drug's potential for abuse.

Zogenix maintains the drug is a necessary option for patients with severe, around-the-clock pain who cannot tolerate acetaminophen.

"Today's legal ruling was a positive step forward for Massachusetts patients," said Zogenix Chief Executive Roger Hawley.

Unlike competing products such as AbbVie Inc's Vicodin and UCB's Lortab, Zohydro does not contain acetaminophen, which has been linked to liver damage.

FDA, in a statement, said it is following the legal proceedings in Massachusetts and remains concerned about efforts by states to ban FDA-approved drugs.

"Both the prevention of prescription opioid abuse and appropriate pain management are top public health priorities at FDA. Actions to advance one should not impede the other," the agency said.

The case was in Re: Zogenix Inc vs Deval Patrick in the U.S. District Court, District of Massachusetts, No. 14-11689-RWZ

(Reporting by Susan Kelly in Chicago and Natalie Grover in Bangalore; Additional reporting by Toni Clarke in Washington; Editing by Savio D'Souza, Jonathan Oatis and Mohammad Zargham)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (2)
KEddie wrote:
Why do stories keep saying this is Zogenix’s only product. How hard is it to look at their website to confirm a simple fact. They had revenue of over 30 million last year from other products. BTW, this is a strong ruling for patient’s rights. It’s nice to see the lies squished in open court.

Apr 15, 2014 6:03pm EDT  --  Report as abuse
FRPSR wrote:
The improper presentation of the issues issued through local media outlets compounded by culling responses that cleared up arguments presented as fact , distortions , and other allusions , through the expediency of simply removing them ! The inferences which alleged overdosed fatalities responsibilities to cause , should , in fact , open an inquiry of its own .
The consequent study to determine the correlation of corruption by degrees of access through political power , easy money , and cozy partisan alliances should prove far more enlightening than a cynical attack against a convenient popular stereotype . The tired , but true , framing of defenseless groups against the object of their needs conflated for the express purpose directing the most profitable determination , creating or preserving , the limited wealth creating venture .

Little need to consider which noble act of claiming young to elderly arthritics whose proportionate use of pharmaceuticals dwarfs the neatly contrived civically promoted conflated assumptions , no indeed…

Let them eat ache .

Apr 16, 2014 9:52am EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.